| First Author | Brandys P | Year | 2022 |
| Journal | Front Immunol | Volume | 13 |
| Pages | 912898 | PubMed ID | 35874687 |
| Mgi Jnum | J:335966 | Mgi Id | MGI:7326030 |
| Doi | 10.3389/fimmu.2022.912898 | Citation | Brandys P, et al. (2022) A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice. Front Immunol 13:912898 |
| abstractText | Two years into the COVID-19 pandemic there is still a need for vaccines to effectively control the spread of novel SARS-CoV-2 variants and associated cases of severe disease. Here we report a messenger RNA vaccine directly encoding for a nanoparticle displaying 60 receptor binding domains (RBDs) of SARS-CoV-2 that acts as a highly effective antigen. A construct encoding the RBD of the Delta variant elicits robust neutralizing antibody response, and also provides protective immunity against the Delta variant in a widely used transgenic mouse model. We ultimately find that the proposed mRNA RBD nanoparticle-based vaccine provides a flexible platform for rapid development and will likely be of great value in combatting current and future SARS-CoV-2 variants of concern. |
